Phaseline

Targets › SLC47A1

SLC47A1 (Multidrug and toxin extrusion protein 1): drug programs, companies and trials

1 program from 1 company in 3 trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Gastroenterology, Oncology, Other; next expected readout Oct 2027.

Multidrug efflux pump that functions as a H(+)/organic cation antiporter. Plays a physiological role in the excretion of cationic compounds including endogenous metabolites, drugs, toxins through the kidney and liver, into urine and bile respectively. (UniProt, Q96FL8)

Open in Phaseline: the race on SLC47A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BayerBAY 2927088 (Sevabertinib)
MATE1 and MATE2-K transporter inhibitor
ERBB2, SLC47A1, SLC47A2Phase 3Advanced Non-small Cell Lung Cancer, HER2 Mutation; Advanced Solid Tumors; Healthy ParticipantsOct 2027

Conditions

Advanced Non-small Cell Lung Cancer, HER2 Mutation (1) Advanced Solid Tumors (1) Healthy Participants (1)

Modalities

small molecule (1)

Companies

Bayer (1)

Related targets

ERBB2 (1) SLC47A2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.